Anthropic launches Claude Science workbench and enters drug discovery, hiring AlphaFold's John Jumper

Anthropic unveiled Claude Science, described as an 'AI workbench for scientists' that unifies fragmented research tools and datasets, generates figures, and streamlines scientific workflows. In a more surprising move, the company signaled it is entering direct drug development, hiring AlphaFold co-creator and Nobel laureate John Jumper — a notable talent coup that rewrites the model-company playbook by pushing Anthropic into applied biotech rather than just selling APIs.

On the infrastructure side, NVIDIA is integrating its BioNeMo NIM microservices into Claude Science, standardizing production deployment of biomolecular models and letting researchers tap NVIDIA-accelerated computational libraries directly inside the workbench. That partnership positions Claude Science as a full-stack scientific platform rather than a chat wrapper.

The timing is striking: it lands the same week Anthropic's Fable/Mythos export ban was lifted, suggesting the company is diversifying its narrative from cybersecurity-risk headlines toward high-value, socially positive scientific applications. It also puts Anthropic into more direct thematic competition with Google DeepMind's Isomorphic Labs on AI-for-drug-discovery.

Caveats and what to watch: 'entering drug development' is a long, capital-intensive road, and hiring one star researcher is a signal, not a pipeline. Reader watch-items include whether Anthropic partners with or acquires wet-lab capacity, how Claude Science is priced for academic vs. pharma users, and whether the BioNeMo integration delivers measurable workflow speedups. The broader AI-for-science mood is buoyant after reports AI helped diagnose 18 children's undiagnosable diseases, though experts caution results still need rigorous validation.